HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

10.150

-0.420-3.97%

Volume:325.00K

Turnover:3.29M

Market Cap:5.26B

PE:-16.42

High:10.500

Open:10.500

Low:9.935

Close:10.570

52wk High:96.900

52wk Low:9.935

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:1.26

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.618

ROE:-19.61%

ROA:-9.68%

PB:3.48

PE(LYR):-16.42

PS:43.64

Loading ...

Overview Company News Filings

Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026

Bulletin Express

Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate

XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR

Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%

Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares

Bulletin Express

XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan

Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares

BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial

BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium

Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment

XuanZhu Bio-B Receives Approval for Phase III Trial of New Anaprazole Sodium Indication

XUANZHUBIO-B Wins CDE Approval to Launch 556-Patient Phase III Trial of Anaprazole Sodium for H. pylori Eradication

Bulletin Express

Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial

Xuanzhu Biopharmaceutical Co Ltd - Approved to Initiate Phase Iii Trial of Anaprazole Sodium for Helicobacter Pylori Eradication

THOMSON REUTERS

Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal

XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals

Xuanzhu Biopharmaceutical secures CSRC approval to convert 357.25 million domestic shares into H-shares

Bulletin Express

XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan

BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology

Xuanzhu Biotech-B Surges Over 10% in Morning Session Following Licensing Pact with Boston Oncology

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02575/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":10.15,"timestamp":1788154240164,"preClose":10.57,"halted":0,"volume":325000,"delay":0,"changeRate":-0.03973509933774834,"floatShares":517947790,"shares":518000000,"eps":-0.618065360706755,"marketStatus":"Trading","change":-0.42,"latestTime":"08-31 13:31:27","open":10.5,"high":10.5,"low":9.935,"amount":3293000,"amplitude":0.053453,"askPrice":10.16,"askSize":1000,"bidPrice":10.11,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.4911345603555724,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788163800000},"marketStatusCode":2,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":10.57,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":1.264562,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-9.68%","roe":"-19.61%","lyrEps":-0.618065,"volumeRatio":1.264562,"shares":518000000,"dividePrice":0,"high":10.5,"amplitude":0.053453,"preClose":10.57,"low":9.935,"week52Low":9.935,"pbRate":"3.48","psRate":"43.64","week52High":96.9,"institutionHeld":0,"latestPrice":10.15,"eps":-0.618065360706755,"divideRate":0,"volume":325000,"delay":0,"ttmEps":-0.4911345603555724,"open":10.5,"prevYearClose":70.5,"prevWeekClose":10.57,"prevMonthClose":10.99,"prevQuarterClose":13.33,"fiveDayClose":10.34,"twentyDayClose":11.58,"sixtyDayClose":17.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-08-28","current":-20.666434,"percent":0.900943,"low":-70.039607,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"high":-18.714723,"avg":-41.794487,"sd":14.235444,"marketCap":5474708140},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557},{"date":"2026-08-28","current":-22.359148,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"marketCap":5474708140}],"updateTime":1788154287895},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1156604450","title":"Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1156604450","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156604450?lang=en_us&edition=fundamental","pubTime":"2026-04-20 17:03","pubTimestamp":1776675811,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm) reported preliminary data from the ongoing Phase 1b FORTRESS study evaluating NG-350A combined with chemoradiotherapy (CRT) in patients with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628574340","title":"Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2628574340","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628574340?lang=en_us&edition=fundamental","pubTime":"2026-04-20 16:51","pubTimestamp":1776675091,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical announced preliminary Phase 1b FORTRESS data for NG-350A were presented at 2026 AACR on April 20, 2026.Early results indicated NG-350A combined with chemoradiotherapy improved response outcomes in mismatch repair-proficient locally advanced rectal cancer versus expectations for chemoradiotherapy alone.Safety profile appeared supportive, with no serious adverse events or new safety signals attributed to NG-350A in initial patients completing active treatment.Program supports Xuanzhu strategy to advance NG-350A development in Greater China under an exclusive license from Akamis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL95R4QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1600","00460","BK1593","BK1515","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126932556","title":"XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1126932556","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126932556?lang=en_us&edition=fundamental","pubTime":"2026-04-19 18:20","pubTimestamp":1776594034,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that the Group presented results from the Phase III DIAMOND-2 clinical study of Diraok as a first-line treatment for anaplastic lymphoma kinase (ALK) positive advanced...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","III","BK4134","BK4008","BK1191","ALK","02575","BK4585","BK4500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628076134","title":"Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628076134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628076134?lang=en_us&edition=fundamental","pubTime":"2026-04-19 18:07","pubTimestamp":1776593223,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical presented Phase III DIAMOND-2 trial results for ALK-positive advanced non-small cell lung cancer at 2026 AACR, held April 17-22, 2026.Dirozalkib outperformed crizotinib in first-line treatment, extending time without disease worsening in a 275-patient China study.Study also showed stronger tumor shrinkage durability, including improved control of brain lesions versus comparator.Safety profile supported continued use, with mostly mild-to-moderate gastrointestinal side effects.Dirozalkib received China NMPA clearance in August 2025 for ALK-positive locally advanced or metastatic NSCLC in patients not previously treated with an ALK inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutica","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL4PxWxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","02575","BK1191","BK1593","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124608444","title":"Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124608444","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124608444?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:05","pubTimestamp":1776416700,"startTime":"0","endTime":"0","summary":"Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189853321","title":"XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1189853321","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189853321?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:34","pubTimestamp":1776414856,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that on April 16, 2026, the Hong Kong Stock Exchange approved the listing and trading of 357 million H-shares. These shares will be converted from non-traded shares as...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628134279","title":"Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2628134279","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628134279?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:31","pubTimestamp":1776414695,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange cleared Xuanzhu Biopharmaceutical to list 357,245,794 H shares converted from unlisted shares under its H-share full circulation plan.Transaction would lift total listed H shares to 517,947,790 from 160,701,996 once conversion and trading procedures are completed.Xuanzhu flagged additional updates as it moves toward completion of conversion and listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL24Xh0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","02575","BK1593","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627502471","title":"BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627502471","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627502471?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:21","pubTimestamp":1776219698,"startTime":"0","endTime":"0","summary":"BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial    ** Shares of Xuanzhu Biopharmaceutical 2575.HK jump as much as 25.8% to HK$41, their highest level since March 26** Stock marks its biggest one-day pct rise since October 22** Xuanzhu says China's National Medical Products Administration has approved the company to initiate a Phase III clinical trial of bismuth-containing quadruple therapy comprising Anaprazole Sodium Enteric-coated tablets for the eradication of Helicobacter pylori** The market size of drugs for treatment of Helicobacter pylori, which closely associated with gastric diseases including gastric ulcer, chronic progressive gastritis and gastric cancer, reached 5.5 billion yuan  in 2024, and is projected to reach 6.8 billion yuan in 2029 and to 12.6 billion yuan in 2035, says Xuanzhu ** The approval of the Phase III clinical trial application for the new indication of Anaprazole Sodium helps to enhance the company's influence in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL1N40Y01E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","00460","BK1191","02575","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627576479","title":"BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium","url":"https://stock-news.laohu8.com/highlight/detail?id=2627576479","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627576479?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:48","pubTimestamp":1776217723,"startTime":"0","endTime":"0","summary":"BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium April 15  - Xuanzhu Biopharmaceutical 2575.HK:APPROVED TO INITIATE PHASE III TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATIONFurther company coverage: 2575.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X16Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180494741","title":"Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1180494741","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180494741?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:38","pubTimestamp":1776217086,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.The biopharmaceutical company received...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194755077","title":"XuanZhu Bio-B Receives Approval for Phase III Trial of New Anaprazole Sodium Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1194755077","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194755077?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:38","pubTimestamp":1776206301,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) announced that its self-developed innovative drug, Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiuwe®), has recently received approval from the Center for Drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","III","BK4134","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161699163","title":"XUANZHUBIO-B Wins CDE Approval to Launch 556-Patient Phase III Trial of Anaprazole Sodium for H. pylori Eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=1161699163","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161699163?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:20","pubTimestamp":1776205235,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (XUANZHUBIO-B) has secured authorisation from China’s Center for Drug Evaluation to begin a multi-centre Phase III study evaluating a bismuth-containing quadruple...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627542752","title":"Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627542752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627542752?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:07","pubTimestamp":1776204421,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical secured China CDE clearance to start Phase III trial of bismuth-containing quadruple therapy using Anaprazole Sodium for Helicobacter pylori eradication.Study targets enrollment of 556 adults, with primary endpoint H. pylori eradication rate confirmed by 13C-urea breath test on day 28.Anaprazole Sodium was approved in China in June 2023 for duodenal ulcer, with new Phase III program aimed at expanding its label into digestive diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9fwX0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","02575","BK1515","BK1191","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627545427","title":"Xuanzhu Biopharmaceutical Co Ltd - Approved to Initiate Phase Iii Trial of Anaprazole Sodium for Helicobacter Pylori Eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=2627545427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627545427?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:06","pubTimestamp":1776204413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132796697","title":"Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1132796697","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132796697?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:12","pubTimestamp":1776147162,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.The sharp rise follows the company's announcement that...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142636519","title":"XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=1142636519","media":"Stock News","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142636519?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:10","pubTimestamp":1776147021,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1191","VXUS","02575","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127927706","title":"Xuanzhu Biopharmaceutical secures CSRC approval to convert 357.25 million domestic shares into H-shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1127927706","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127927706?lang=en_us&edition=fundamental","pubTime":"2026-04-12 18:21","pubTimestamp":1775989280,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. announced that it has received an official notification from the China Securities Regulatory Commission (CSRC) confirming completion of its filing for an H-share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165876354","title":"XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1165876354","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165876354?lang=en_us&edition=fundamental","pubTime":"2026-04-12 18:06","pubTimestamp":1775988373,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626116838","title":"BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2626116838","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626116838?lang=en_us&edition=fundamental","pubTime":"2026-04-10 11:06","pubTimestamp":1775790406,"startTime":"0","endTime":"0","summary":"BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology** Shares of drugmaker Xuanzhu Biopharmaceutical 2575.HK jump 18.1% to HK$37** Set for the biggest one-day pct rise since Oct 22** Stock also hit highest level since March 27 in the fifth session of gain** Cambridge, Massachusetts-based oncology drugmaker Boston Oncology CGT Holding will license Xuanzhu's breast cancer treatment Bireociclib and lung cancer treatment Dirozalkib** Payments to exceed $100 million if milestones are met ** Under agreement, Sihuan Pharmaceutical 0460.HK unit Xuanzhu is eligible to receive an upfront payment, regulatory and sales-related milestone payments, royalties based on sales** YTD, Xuanzhu stock down 50.6%, while Sihuan Pharmaceutical shares up 15.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL1N40T02K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","BK1191","00460","02575","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117603074","title":"Xuanzhu Biotech-B Surges Over 10% in Morning Session Following Licensing Pact with Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1117603074","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117603074?lang=en_us&edition=fundamental","pubTime":"2026-04-10 09:38","pubTimestamp":1775785106,"startTime":"0","endTime":"0","summary":"Xuanzhu Biotech-B (02575) saw its shares rise more than 10% during the morning trading session. At the time of writing, the stock was up 9.96%, trading at HK$34.46 with a turnover of HK$3.4138...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1191","02575","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":87,"code":"91000000","status":"200"}]}}